US 12,441,785 B2
Methods of treating inflammatory diseases
Matthias Arndt, Laupheim (DE); Stella Aslanyan, Danbury, CT (US); Mary Ruth Flack, Ridgefield, CT (US); Annette Bettina Galler, Armsheim (DE); Bojan Lalovic, Cedar Knolls, NJ (US); Steven John Padula, Southbury, CT (US); and Paul Russell Scholl, Redding, CT (US)
Assigned to Boehringer Ingelheim International GmbH, Ingelheim am Rhein (DE)
Filed by Boehringer Ingelheim International GmbH, Ingelheim am Rhein (DE)
Filed on Feb. 2, 2016, as Appl. No. 15/013,008.
Claims priority of provisional application 62/235,631, filed on Oct. 1, 2015.
Claims priority of provisional application 62/204,520, filed on Aug. 13, 2015.
Claims priority of provisional application 62/145,764, filed on Apr. 10, 2015.
Claims priority of provisional application 62/135,335, filed on Mar. 19, 2015.
Claims priority of provisional application 62/130,876, filed on Mar. 10, 2015.
Claims priority of provisional application 62/111,731, filed on Feb. 4, 2015.
Prior Publication US 2016/0222102 A1, Aug. 4, 2016
Int. Cl. C07K 16/24 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/244 (2013.01) [A61K 2039/505 (2013.01); A61K 2039/545 (2013.01); C07K 2317/76 (2013.01)] 80 Claims
 
1. A method for treating moderate to severe plaque psoriasis in an adult human patient with moderate to severe plaque psoriasis, comprising administering to the patient a safe and therapeutically effective dosing regimen of a full-length anti-IL-23A antibody, said anti-IL-23A antibody comprising two light chains each having the amino acid sequence of SEQ ID NO: 18 and two heavy chains each having the amino acid sequence of SEQ ID NO: 19, wherein said treating is significantly reducing or completely clearing psoriatic skin lesions, the dosing regimen comprising:
a) subcutaneously administering to the patient a first dose of 150 mg of said anti-IL-23A antibody regardless of the patient's body weight; and
b) subcutaneously administering to the patient a second dose of 150 mg of said anti-IL-23A antibody regardless of the patient's body weight 4 weeks after said first dose is administered,
wherein the method results in the patient achieving at least a 90% reduction from baseline Psoriasis Area and Severity Index score (PASI 90) 12 weeks after receiving the first dose.